Datum |
Zeit |
Quelle |
Überschrift |
02.5.2024 | 15:00 | GLOBE | Nuwellis Receives USPTO Notice of Patent Allowance for.. |
01.5.2024 | 00:09 | GLOBE | Nuwellis Announces Closing of $2.7 Million Public Offering |
30.4.2024 | 22:41 | GLOBE | Nuwellis, Inc. To Report First Quarter 2024 Financial.. |
26.4.2024 | 15:17 | GLOBE | Nuwellis Announces Pricing of $2.7 Million Public Offering |
09.4.2024 | 15:00 | GLOBE | Nuwellis Announces Launch of Ultrafiltration Therapy Using.. |
11.3.2024 | 22:08 | EDGAR2 | Form 10-K - Annual report [Section 13 and 15(d), not S-K.. |
07.3.2024 | 15:08 | GLOBE | Late-Breaking Data Highlighting Benefits of Ultrafiltration.. |
06.3.2024 | 18:02 | EDGAR2 | Form 8-K - Current report |
05.3.2024 | 14:00 | GLOBE | Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023.. |
05.3.2024 | 12:05 | IHMARKETNEWS | U.S. Futures Dip, Crude Oil Fluctuates |
27.2.2024 | 15:00 | GLOBE | Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023.. |
22.2.2024 | 13:58 | GLOBE | Nuwellis’ Distribution Partner, SeaStar Medical, Receives.. |
20.2.2024 | 23:06 | GLOBE | Nuwellis, Inc. Reports Inducement Grants Under Nasdaq.. |
20.2.2024 | 14:42 | GLOBE | Nuwellis to Announce Late-Breaking Clinical Data and Host.. |
08.2.2024 | 23:19 | EDGAR2 | Form S-1/A - General form for registration of securities.. |
06.2.2024 | 15:07 | EDGAR2 | Form 8-K - Current report |
06.2.2024 | 15:00 | GLOBE | New Case Series Demonstrates Potential of Aquadex Therapy.. |
09.1.2024 | 23:30 | EDGAR2 | Form 8-K/A - Current report: [Amend] |
08.1.2024 | 15:24 | EDGAR2 | Form 8-K - Current report |
04.1.2024 | 22:25 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
04.1.2024 | 21:05 | GLOBE | Nuwellis Receives FDA Clearance for an Additional Dual Lumen.. |
13.12.2023 | 22:05 | EDGAR2 | Form 8-K - Current report |
28.11.2023 | 14:00 | GLOBE | New Real-World Data Highlight the Clinical Benefits of.. |
14.11.2023 | 22:30 | GLOBE | Nuwellis, Inc. Reports Inducement Grants Under Nasdaq.. |
07.11.2023 | 16:00 | EDGAR2 | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
07.11.2023 | 14:15 | EDGAR2 | Form 8-K - Current report |
07.11.2023 | 14:00 | GLOBE | Nuwellis, Inc. Announces Third Quarter 2023 Financial.. |
01.11.2023 | 21:15 | EDGAR2 | Form 8-K - Current report |
01.11.2023 | 13:00 | GLOBE | Nuwellis Announces Board of Directors Transition |
31.10.2023 | 13:00 | GLOBE | Nuwellis’ Strategic Partner, SeaStar Medical, Receives FDA.. |
18.10.2023 | 22:15 | GLOBE | Nuwellis, Inc. To Announce Third Quarter 2023 Financial.. |
17.10.2023 | 22:30 | EDGAR2 | Form 8-K - Current report |
17.10.2023 | 22:15 | GLOBE | Nuwellis Announces Closing of $2.25 Million Public Offering.. |
13.10.2023 | 14:30 | GLOBE | Nuwellis Announces Pricing of $2.25 Million Public Offering.. |
10.10.2023 | 14:30 | EDGAR2 | Form 8-K - Current report |
10.10.2023 | 14:00 | GLOBE | Nuwellis Provides Regulatory Update on SeaStar Medical’s.. |
06.10.2023 | 22:50 | EDGAR2 | Form POS462C - Post-effective amendment to registration.. |
05.10.2023 | 15:27 | EDGAR2 | Form AW - Amendment Withdrawal Request |
04.10.2023 | 23:29 | EDGAR2 | Form POS AM - Post-Effective amendments for registration.. |
02.10.2023 | 06:15 | EDGAR2 | Form EFFECT - Notice of Effectiveness |
29.9.2023 | 14:56 | EDGAR2 | Form S-1/A - General form for registration of securities.. |
11.9.2023 | 22:15 | GLOBE | Nuwellis to Present at the Gilmartin Group Emerging Growth.. |
06.9.2023 | 22:23 | EDGAR2 | Form 4 - Statement of changes in beneficial ownership of.. |
06.9.2023 | 22:12 | EDGAR2 | Form 3 - Initial statement of beneficial ownership of.. |
18.8.2023 | 22:56 | EDGAR2 | Form 8-K - Current report |
08.8.2023 | 18:09 | EDGAR2 | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
08.8.2023 | 14:25 | EDGAR2 | Form 8-K - Current report |
08.8.2023 | 14:15 | EDGAR2 | Form 8-K - Current report |
08.8.2023 | 14:15 | GLOBE | Nuwellis, Inc. Announces Second Quarter 2023 Financial.. |
08.8.2023 | 14:00 | GLOBE | Nuwellis Announces Plan for CFO Transition |